PCSK9 and cardiovascular disorder: Heart transplant recipients, due to higher primary cardiovascular disease risk (with 90% having ASCVD ≥7.5%), may be more responsive to PCSK9 inhibitors, while liver transplant recipients exhibited lower risk (60%), which may be related to metabolic differences.